Penumbra (NYSE:PEN) Shares Down 8.1% – Time to Sell?

Penumbra, Inc. (NYSE:PEN) traded down 8.1% during trading on Tuesday . The company traded as low as $290.00 and last traded at $293.4720. 307,546 shares were traded during mid-day trading, a decline of 43% from the average session volume of 540,200 shares. The stock had previously closed at $319.47.

Penumbra News Roundup

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra in a cash-and-stock transaction valuing Penumbra at $374 per share (~$14.5B), delivering a substantial premium to the prior market price and directly supporting upward pressure on PEN shares. Boston Scientific to acquire Penumbra in $14.5B deal
• Positive Sentiment: Penumbra issued a preliminary fourth-quarter and full‑year 2025 update and offered revenue guidance that was in-line-to-better-than consensus, reinforcing the company’s underlying operating strength and making the deal appear accretive to holders. Penumbra preliminary update
• Neutral Sentiment: Deal mechanics: the transaction offers $374.00 in cash or 3.8721 shares of Boston Scientific common stock, so final value to holders depends partly on BSX shares and customary closing conditions (regulatory approval, shareholder votes). That introduces some counterparty/market risk to the headline price. Deal terms and stock/cash mix
• Negative Sentiment: Multiple law firms have opened investigations and are soliciting clients to challenge whether the sale process and price are fair to Penumbra shareholders (Monteverde & Associates, Ademi LLP, Brodsky & Smith, Halper Sadeh, etc.). These lawsuits or proxy disputes could delay closing, force renegotiation, or create settlement costs — a material legal overhang. Monteverde investigation Ademi investigation

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC boosted their price target on shares of Penumbra from $326.00 to $388.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded Penumbra from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Citigroup cut Penumbra from a “buy” rating to a “neutral” rating in a research report on Thursday. Wells Fargo & Company restated an “equal weight” rating and set a $374.00 price target on shares of Penumbra in a research note on Thursday. Finally, Bank of America lifted their price target on Penumbra from $320.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Ten research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Penumbra currently has a consensus rating of “Moderate Buy” and a consensus price target of $350.87.

Penumbra Stock Up 11.8%

The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. The firm’s 50 day moving average price is $301.84 and its two-hundred day moving average price is $268.86. The firm has a market cap of $13.73 billion, a price-to-earnings ratio of 83.86, a P/E/G ratio of 1.92 and a beta of 0.71.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. During the same period in the prior year, the business earned $0.85 EPS. The firm’s revenue was up 17.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Arani Bose sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $308.82, for a total value of $4,632,300.00. Following the completion of the sale, the director owned 258,462 shares in the company, valued at approximately $79,818,234.84. This trade represents a 5.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $310.72, for a total transaction of $57,793.92. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 34,144 shares of company stock valued at $10,260,127 in the last ninety days. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Machina Capital S.A.S. purchased a new stake in shares of Penumbra in the 2nd quarter worth about $369,000. First Trust Advisors LP increased its holdings in Penumbra by 4.0% during the 2nd quarter. First Trust Advisors LP now owns 100,723 shares of the company’s stock valued at $25,849,000 after acquiring an additional 3,906 shares in the last quarter. Russell Investments Group Ltd. raised its position in Penumbra by 22.9% during the second quarter. Russell Investments Group Ltd. now owns 26,604 shares of the company’s stock worth $6,827,000 after acquiring an additional 4,960 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Penumbra by 716.5% in the second quarter. Janney Montgomery Scott LLC now owns 24,749 shares of the company’s stock valued at $6,351,000 after purchasing an additional 21,718 shares in the last quarter. Finally, Marshall Wace LLP grew its position in shares of Penumbra by 340.0% in the second quarter. Marshall Wace LLP now owns 82,031 shares of the company’s stock valued at $21,052,000 after purchasing an additional 63,389 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.